SAINTE-FOY, QUEBEC--(CCNMatthews - Dec. 16, 2005) - Bioxel Pharma Inc. (TSX VENTURE:BIP), a leading manufacturer of taxane active pharmaceutical ingredients (APIs) and developer of targeted oncology drugs, today announced that it has secured approximately $273,000 to support formulation development of anticancer drugs.
